Literature DB >> 23219022

Survey of prophylactic use of uterotonics in the third stage of labour in the Netherlands.

M Smit1, G van Stralen, R Wolterbeek, J van Dillen, J van Roosmalen, Y Slootweg.   

Abstract

OBJECTIVE: aim of this study was to investigate current knowledge and practice regarding AMTSL in midwifery practices and obstetric departments in the Netherlands.
DESIGN: web-based and postal questionnaire.
SETTING: in August and September 2011 a questionnaire was sent to all midwifery practices and all obstetric departments in the Netherlands. PARTICIPANTS: all midwifery practices (528) and all obstetric departments (91) in the Netherlands. MEASUREMENTS AND
FINDINGS: the response was 87.5%. Administering prophylactic uterotonics was seen as a component AMTSL by virtually all respondents; 96.1% of midwives and 98.8% of obstetricians. Cord clamping was found as a component of AMTSL by 87.4% of midwives and by 88.1% of obstetricians. Uterine massage was only seen as a component of AMTSL by 10% of the midwives and 20.2% of the obstetricians. Midwifery practices routinely administer oxytocin in 60.1% of births. Obstetric departments do so in 97.6% (p<0.01). Compared to 1995, the prophylactic use of oxytocin had increased in 2011 both by midwives (10-59.1%) and by obstetricians (55-96.4%) (p<0.01). KEY
CONCLUSIONS: prophylactic administration of uterotonics directly after childbirth is perceived as the essential part of AMTSL. The administration of uterotonics has significantly increased in the last decade, but is not standard practice in the low-risk population supervised by midwives. IMPLICATIONS FOR PRACTICE: the evidence for prophylactic administration of uterotonics is convincing for women who are at high risk of PPH. Regarding the lack of evidence of AMTSL to prevent PPH in low risk (home) births, further research concerning low-risk (home) births, supervised by midwives in industrialised countries is indicated. A national guideline containing best practices concerning management of the third stage of labour supervised by midwives, should be composed and implemented.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Active management of the third stage of labour; Midwife; Obstetrician; Uterotonics

Mesh:

Substances:

Year:  2012        PMID: 23219022     DOI: 10.1016/j.midw.2012.09.004

Source DB:  PubMed          Journal:  Midwifery        ISSN: 0266-6138            Impact factor:   2.372


  5 in total

1.  Knowledge and barriers on correct use of modified guidelines for active management of third stage of labour: a cross sectional survey of nurse-midwives at three referral hospitals in Dar es Salaam, Tanzania.

Authors:  Fatina B Ramadhani; Yilan Liu; Melania Menrad Lembuka
Journal:  Afr Health Sci       Date:  2020-12       Impact factor: 0.927

2.  Effect of maternal oxytocin on umbilical venous and arterial blood flows during physiological-based cord clamping in preterm lambs.

Authors:  Fiona J Stenning; Graeme R Polglase; Arjan B Te Pas; Kelly J Crossley; Martin Kluckow; Andrew W Gill; Euan M Wallace; Erin V McGillick; Corinna Binder; Douglas A Blank; Calum Roberts; Stuart B Hooper
Journal:  PLoS One       Date:  2021-06-17       Impact factor: 3.240

Review 3.  Literature Review: Physiological Management for Preventing Postpartum Hemorrhage.

Authors:  Wedad M Almutairi
Journal:  Healthcare (Basel)       Date:  2021-05-31

4.  The development of quality indicators for the prevention and management of postpartum haemorrhage in primary midwifery care in the Netherlands.

Authors:  Marrit Smit; Susanne I C Sindram; Mallory Woiski; Johanna M Middeldorp; Jos van Roosmalen
Journal:  BMC Pregnancy Childbirth       Date:  2013-10-20       Impact factor: 3.007

5.  Use of prophylactic uterotonics during the third stage of labor: a survey of provider practices in community health facilities in Sierra Leone.

Authors:  Abirami Natarajan; Roy Ahn; Brett D Nelson; Melody Eckardt; Jennifer Kamara; Sas Kargbo; Pity Kanu; Thomas F Burke
Journal:  BMC Pregnancy Childbirth       Date:  2016-01-28       Impact factor: 3.007

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.